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the macrocycle, and additional masking of polarity. In this 
study, we investigate further the pivotal effects of shield-
ing on permeability and studied the metabolism of the cor-
responding peptides in more detail by comparing peptide 
concentrations in the portal versus the jugular vein in rats. 
Interestingly, minor changes in one particular side chain 
impacts both permeability and liver metabolism.
Abstract Recently, a variety of studies concerned with 
the permeability and oral bioavailability of cyclic peptides 
have been reported. In particular, strategies aiming at modi-
fying peptides to maintain or to enhance solubility while 
enabling permeability constitute a significant challenge, 
but are of high interest to ensure a smooth drug discovery 
process. Current methodologies include N-methylation, 
matching of hydrogen bonding acceptors and donors across 
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Abbreviations
ADME  Absorption, distribution, metabolism, and 
excretion
AUC  Area under the curve
%BAV  Bioavailability on p.o. administration
CL  In vitro or in vivo clearance
Cmax  Observed maximum concentration in blood
d.n.  Dose normalized
H.P.V  Hepatic portal vein
i.v.  Intravenous
LLOQ  Lower limit of quantification
MDCK  Madin Darby canine kidney cells
MLM  Mouse liver microsomes
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MRT  Mean residence time
PAMPA  Parallel Artificial Membrane Permeability 
Assay
PK  Pharmacokinetics
PPB  Plasma-protein binding
rmsd  Root mean squared deviation
p.o.  Per os
PSA  Polar surface area
SAPSA  Solvent-accessible polar surface area
SFC  Supercritical fluid chromatography
T1/2 term  Terminal half-life for elimination
Tmax  Time of observed maximal blood concentration
Vss  Apparent volume of distribution at steady state
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Introduction
The improvement of absorption, distribution, metabolism, 
and excretion (ADME) properties for peptides is of utmost 
importance to broaden applications for macromolecules, 
e.g. to enable delivery by the oral route. Principal studies 
to elucidate the role of the backbone and side chains for a 
given cyclic peptide with respect to permeability, and in 
particular oral uptake, are of value to learn more about the 
required property space. In principle, this know-how can 
then be systematically applied to design permeable and 
potent macromolecules in an iterative fashion, and should 
encourage a straight forward development of orally bio-
available peptide therapeutics. Especially, the promotion of 
permeability while maintaining a good solubility remains 
a significant challenge and is of interest in our investiga-
tion (Marzinzik and Vorherr 2013; Vorherr 2015; Kwon 
and Kodadek 2007). This intense effort on macromolecules 
has become extremely important, since for many attractive 
drug targets no high affinity and selective small molecules 
complying with the “rule-of-five” (Krämer et  al. 2016; 
Whitty et al. 2016) can be identified. This rule, originally 
published by Lipinski et al. (2001), represents an empirical 
evaluation of the suitability of a given molecule or class of 
molecules towards favorable oral bioavailability in humans. 
However, macromolecules were not in the focus, and the 
original guidelines, e.g. molecular weight ≤ 500, were 
extended (molecular weight ≤ 720 and polar surface area 
remaining at ≤140 Å2) (Veber et al. 2002). More recently 
(Villar et al. 2014), a molecular weight range of 600–1200 
and values for the polar surface area of 180–320 Å2 were 
reported as a potential space for oral drugs. Thus, stepping 
outside the limited chemical space seems possible and may 
offer opportunities to find molecules with high potency 
and selectivity. However, there is a need to obtain appro-
priate properties to render particular ligands druggable 
even though the route of administration requires transport 
across certain barriers, e.g. crossing the intestinal mucosa 
to achieve systemic exposure.
In a previous investigation, we introduced the concept of a 
polar surface assessment in 3D called solvent-accessible polar 
surface area (SAPSA), and showed the correlation of in vitro 
permeability on cyclic hexapeptides (1) and (2) (Fig.  1) 
with the in vivo oral bioavailability (%BAV) as indicated in 
Table  2 for peptides (1) and (2) (Lewis et  al. 2015). How-
ever, taking peptide (2) as an example of multiple N-meth-
ylation, solubility is considerably reduced, and as expected, 
a substantial increase of oral bioavailability was observed. 
In a recent publication, effects of N-methylation on aqueous 
solubility based on considerations of increased polarity and 
flexibility have been suggested from an in-silico assessment 
of the various amino acids and their corresponding N-methyl-
ated counterparts (Rauf et al. 2015). In these calculations, all 
N-methylated amino acid derivatives showed a larger dipole 
moment as compared to the non-methylated amide bond. 
Since the contribution of single dipoles to polarity in the 
context of a cyclic peptide is not clear to us, in this contribu-
tion, we define polarity as the ability to interact with H-bond 
acceptors and donors. In order to ensure an optimal develop-
ment path, we thought of modifications improving solubility 
while maintaining permeability. Furthermore, we wanted to 
study structurally related derivatives to enable comparability 
with the previous studies. In a first step, we decided to reduce 
the degree of N-methylation. Indeed, a variety of publications 
on N-Methylation have emerged (Krämer et al. 2016; Biron 
et  al. 2008; White et  al. 2011). Most interestingly, a recent 
design to improve on the natural product Sanguinamide 
A (Nielsen et  al. 2012) clearly showed that N-methylation 
does not always enhance oral uptake (Nielsen et  al. 2014). 
Of course, the question may arise whether a lower degree of 
N-methylation encourages flexibility in a cyclic peptide (Rauf 
et al. 2015), and as a consequence, adds more or less chame-
leonic properties to the molecule (Whitty et al. 2016). More 
generally, we aimed to increase the understanding of how to 
modulate properties of macrocyclic drugs (Giordanetto and 
Kihlberg 2014), and to rationalize the impact of structural 
features enhancing “drug-like” properties (Over et al. 2014). 
Special building blocks enabling shielding or masking of 
polarity by formation of intramolecular hydrogen bonds have 
been reported (Rafi et  al. 2012), however in the context of 
these studies focused on peptides (3)–(5), we concentrated on 
replacing the polar Tyr to study the influence of differentially 
sized apolar groups. In addition to our particular 3D polar 
surface calculation called SAPSA and the more classical 
profiling by parallel artificial membrane permeability assay 
(PAMPA) and Madin Darby canine kidney cells (MDCK) 
applied earlier (Lewis et al. 2015), we used the experimental 
determination of polar surfaces as measured by supercritical 
fluid chromatography (SFC) (Goetz et al. 2014a, b) to charac-
terize cyclic peptides for permeability. The focus of this study 
was to better understand contributions of intestinal uptake 
and clearance/metabolism to the observed exposure upon oral 
administration in the selected model systems. In our opinion, 
a deeper understanding of certain pharmacokinetic param-
eters will provide guidance how to improve properties, and 




Amino acids, reagents and solvents were purchased from 
Bachem or Aldrich. Two synthetic strategies were utilized 
in the preparation of the cyclic peptides described. Cyclic 
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peptides (1) and (2) were synthesized, using the first syn-
thetic strategy, starting with the allyl ester of fluorenyl-
methyloxycarbonyl (Fmoc)-protected tyrosine linked to 
a trityl polystyrene resin (TentaGel S Trt Cl from RAPP 
Polymere GmbH) via the –OH of the tyrosine side-chain. 
Cyclization was performed on-resin, after deprotection of 
the allyl ester, followed by cleavage of the cyclic peptide 
from the resin, as previously described (Lewis et al. 2015). 
Peptides (3)–(5) were prepared utilizing the second syn-
thetic strategy, with attachment of the Fmoc-D-Pro residue 
via the C-terminal carboxy group to the 2-Cl-Trt-resin and 
assembly of the linear peptide on the resin. Peptides were 
prepared using a Symphony automated peptide synthesizer, 
cleaved from the resin, subsequently cyclized in solution 
and purified by prep. HPLC. Typically, peptides were syn-
thesized as follows: Fmoc removal was performed using 
4-methylpiperidine/DMF 1:4 (2 × 5 min, 5 mL). The resin 
was washed with DMF (×3) and DCM (×4) for 10  min 
each. Coupling of AAs was performed using 2 Eq.  of 
Fmoc-AA-OH, 4.0  Eq.  of HATU and 8.0 Eq.  of DIPEA 
at room temperature. Subsequently, the resin was washed 
with DMF (×3) and DCM (×4). The linear peptide resin 
was cleaved from the resin by shaking at room tempera-
ture for 3 × 10 min then 1 × 5 min with HFIP/DCM (25:75) 
(6 mL each time). The resin was then washed with DCM 
(2×) and the cleavage and washing solutions were filtered 
off then concentrated to dryness in vacuo. Subsequent to 
cleavage, cyclization was carried out in solution. Typically 
a 500 mL round-bottomed flask was equipped with a mag-
netic stirrer and stirring was carried out at 40 °C for several 
hours. Preparative reversed phase purification was carried 






































































Fig. 1  Cyclohexapeptides (1)–(5)
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OBD, 30 × 250 mm; Waters Part No 186004025; Eluent A: 
0.1% TFA in water; Eluent B: MeCN; Flow: 30  mL/min; 
Gradient  : 30%B in 30  min 100%B, fractions collected 
with a Waters 2767 Sample Manager and UV detection 
with a Waters 2996 Photo Diode Array Detector linked to a 
Waters 2525 Binary Gradient Module Pump.
Compound (3):  H2N-Phe-Leu-NMe-D-Leu-NMe-Leu- 
Leu-D-Pro-OH (216  mg, 0.291  mmol) was dissolved in 
DCM (90  mL) to provide solution A. Solution B was 
prepared by dissolving HOAt (59.4  mg, 0.436  mmol), 
HATU (442 mg, 1.163 mmol) and 2,6-lutidine (1.016 mL, 
8.72 mmol) in DCM (200 mL). Then solution A was added 
to solution B dropwise and the reaction was stirred at RT 
for 2  h then concentrated to dryness in vacuo. Purifica-
tion was carried out by preparative HPLC eluting from 
5%MeCN/water to 70%MeCN/water in 17  min and pure 
fractions were combined and lyophilized, affording the 
desired compound (3) [Phe-Leu-NMe-D-Leu-NMe-Leu-
Leu-D-Pro] (110  mg, 0.152  mmol, 52.2% yield, >98% 
purity, (M + H) + = 725.49) as a white lyophilisate.
Compound (4):  H2N-Abu-Leu-NMe-D-Leu-NMe-Leu- 
Leu-D-Pro-OH (136  mg, 0.200  mmol), was dissolved in 
DCM (50 mL) to provide solution A. Solution B was pre-
pared by dissolving HOAt (40.8  mg, 0.300  mmol) and 
HATU (304  mg, 0.800  mmol) in DCM (200  mL) and 
2,6-lutidine (0.699 mL, 6.00 mmol). Then solution A was 
added to solution B dropwise and the reaction was stirred at 
40 °C for 2h, then concentrated to dryness in vacuo. Puri-
fication was carried out by preparative HPLC eluting from 
5%MeCN/water to 70%MeCN/water in 17  min and pure 
fractions were combined and lyophilized, affording the 
desired compound (4) [Abu-Leu-NMe-D-Leu-NMe-Leu-
Leu-D-Pro] (47.8  mg, 0.072  mmol, 36.1% yield, >98% 
purity, (M + H) + = 663.48) as a white lyophilisate.
Compound (5):  H2N-Ala-Leu-NMe-D-Leu-NMe-Leu- 
Leu-D-Pro-OH (300  mg, 0.450  mmol) was dissolved in 
MeCN (35  mL) to provide solution A. Solution B was 
prepared by dissolving HATU (513  mg, 1.350  mmol, 
3 eq.) and DIPEA (470 μL, 2.70 mmol, 6.0 eq.) in MeCN 
(25 mL). Then, solution 1 was added dropwise (90 mL/h) 
in 20  min to solution 2 and the reaction was stirred for 
1  h at RT, then concentrated to dryness in vacuo. Purifi-
cation was carried out by preparative HPLC eluting from 
5%MeCN/water to 70%MeCN/water in 17  min and pure 
fractions were combined and lyophilized, affording the 
desired compound (5) [Ala-Leu-NMe-D-Leu-NMe-Leu-
Leu-D-Pro] (120  mg, 0.178  mmol, 39.5% yield, >95% 
purity, (M + H) + = 649.5) as a white lyophilisate.
Analytical data (UPLC, MS, NMR) is contained in the 
supplementary information including the chromatograms 
and spectra in Figures S1 and S2.
Assays for Microsomal Clearance, Permeability, 
Protein Binding, and Solubility
Protocols for high-throughput equilibrium solubility, 
PAMPA, cellular permeability by the native MDCK assay, 
plasma protein binding, and microsomal clearance experi-
ments were followed as reported earlier (Lewis et al. 2015). 
The values relate to single experiments. For the MDCK 
assay, the lower limit of quantification (LLOQ) was 5 nM, 
and for PAMPA 2  nM, respectively. For both PAMPA 
and MDCK, the standard deviation in log units for those 
assays is 0.2 (1.6-fold on a linear scale). This has been esti-
mated by looking at independent replicates across the assay 
dynamic range.
SAPSA
Molecular dynamics simulations were performed over 
20  ns for every peptide using an implicit solvent model 
of water (Schaefer and Karplus 1996) generating a set 
of 20,000 conformations for each as previously reported 
(Lewis et  al. 2015). The initial 3-dimensional structures 
were generated using the program Corina (Sadowski 
et al. 1994). Before starting data collection, the peptides 
were minimized for 400 steps and heated to 300  K by 
performing 10 ps Langevin dynamics. A water model was 
applied for the dynamics, rather than a model represent-
ing the membrane interior (e.g., chloroform), since this 
leads to faster transitions between conformations in the 
simulations and better sampling of conformation space 
(Chen et al. 2008). For every structure thus obtained, we 
computed the 3-dimensional solvent-accessible polar sur-
face area. By averaging over all conformations, we deter-
mined the time-averaged, solvent accessible surface area 
(SAPSA) of the peptides. Conformational changes and 
the dynamic formation of hydrogen bonds were facili-
tated by a high dielectric constant of 80 representing 
water as the solvent, and a low friction constant of 1/ps 
for performing constant temperature Langevin dynamics 
(Brooks et al. 1983). The SAPSA for each frame is deter-
mined as the area covered by the center of a solvent probe 
sphere with a radius of 1.4  Å in contact with oxygen, 
nitrogen, and their bonded hydrogens (Richmond 1984). 
For the solute atoms, we employ the same Bondi radii as 
are used to compute the conventional polar surface area 
(PSA) (Ertl et al. 2000). A more detailed comparison was 
carried out for the two closely related peptides (4) and 
(5). In order to verify, whether a reduced SAPSA is the 
result of direct shielding or is induced by the side-chain 
affecting the conformation of the scaffold, in the trajec-
tory of peptide (4), the terminal  CH3-group of Abu was 
replaced by a hydrogen atom to match the structure of 
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peptide (5). Then, the SAPSA was calculated for this arti-
ficial trajectory and compared to the outcome from the 
standard simulations of peptides (4) and (5) (Fig. 3).
SFC
Conditions for analytical supercritical fluid chromatogra-
phy (SFC) were taken from previous publications (Goetz 
et al. 2014a, b). The Pirkle chiral stationary phase Chirex 
3014, a silica bonded (S)-valine and (R)-1-(α-naphthyl)
ethylamine with a urea linkage, was selected. A mobile 
phase of 15% methanol in supercritical  CO2 enabled ade-
quate separation in combination with a low-slope gradi-
ent. High retention times were mitigated by increasing 
the percentage of methanol in the eluent and the addition 
of the relatively weak salt pair ammonium formate. In the 
resulting chromatographic system, differences in reten-
tion depend upon hydrophobic interactions, the ability 
for hydrogen bonding, the presence of dipoles, and van 
der Waals interactions of the solutes with the stationary 
phase (Goetz et al. 2014a, b).
Proteolytic Stability
Peptides (1)–(5) were studied for stability in rat blood, kid-
ney, and liver homogenate. Pre-weighed tissues from rat 
were homogenized with three part volume of DPBS buffer 
by the Dispomix™ device. 5  μL of the corresponding 
working solution (c = 400  μM in dimethylsulfoxide) were 
spiked in 400 μL pre-warmed to 37 °C matrix. At the time 
points 0, 0.25, 0.5, 1, 2 and 4 h (in duplicate), an aliquot 
of 30 μL was taken and added to 200 μL MeCN (includ-
ing Glyburide c = 50 ng/mL as an internal standard for pro-
tein precipitation). Sample analysis was performed on a 
Thermo Finnigan Q Exactive hybrid quadrupole-Orbitrap 
mass spectrometer equipped with a Heated Electrospray 
Ionization (HESI-II) Probe (Waltham, Massachusetts, 
U.S.A.). The MS system was connected to a Thermo Sci-
entific Dionex UltiMate 3000 System (Waltham, Massa-
chusetts, U.S.A.). The supernatants (2  µL) were injected 
directly onto the LC-HRMS system for analysis. The test 
articles and its internal standard were separated with a Phe-
nomenex Kinetex C18 (50 × 2 mm ID, 2.7 µm pore size). A 
binary gradient with a mobile phase consisting of water (A) 
and MeCN (B) was used for the LC-separation. The both 
mobile phases (A) and (B) were acidified with 0.1% formic 
acid. The elution gradient program was as follows: [time 
(min), (% mobile phase B): (0, 30) (4, 90) (4.1, 98) (5, 98) 
(5.1, 30) (7, 30)]. The column temperature was maintained 
at 50 °C using a column heater. Under these experimental 
conditions, the LLOQ was 10 ng/mL.
In Vivo Studies
Mouse PK studies on peptides (1)–(3) were performed 
in OF1 mice at a dosing of 2.1 mg/kg i.v. and 7.1 mg/kg 
p.o. [peptides (1) and (2)], and 1 mg/kg i.v. and 7.5 mg/kg 
p.o. for peptide (3) as described earlier (Lewis et al. 2015). 
For mouse PK on peptides (4) and (5), blood concentra-
tions versus time profiles were obtained from 2 groups of 
3 male C57Bl/6 mice. In the intravenous PK group (n = 3), 
the compound was administered intravenous (i.v.) by bolus 
injection (5  mL/kg) at a dose of 1  mg/kg, solubilized in 
N-Methyl-2-pyrrolidone (10%) and blank plasma (90%). 
For oral PK, another group of 3 male C57Bl/6 mice, a dose 
of 3 mg/kg was orally applied (dosing volume of 10 mL/
kg) as a homogenous suspension of water (99%), Tween80 
(0.5%) and methylcellulose (0.5%).
For rat PK, blood concentration versus time profiles 
were obtained from 3 male Sprague Dawley rats. For intra-
venous PK, the compound was administered intravenously 
by bolus injection (0.5 mL/kg) at a dose of 3 mg/kg, solubi-
lized in N-Methyl-2-pyrrolidone (30%) and PEG200 (70%). 
For oral PK, after a washout period of 48 h, an oral gavage 
was administered to the same animals at a dose of 3 mg/kg 
at a dosing volume of 2.5 mL/kg. The oral dose was dis-
persed in water (99%), Tween80 (0.5%) and methylcellu-
lose (0.5%), forming a homogenous suspension. For both 
rodents, blood samples (10–50 µL) were collected at 0.08 
(i.v. only), 0.25, 0.5, 1, 2, 4, 7, and 24 h after dosing. To 
investigate the absorption and the impact of pre-systemic 
metabolism, the model of portal vein cannulation in rats 
was applied for compounds orally dosed in a cassette. The 
week before the PK experiments, the rats were surgically 
prepared with catheter implantation into the right jugular 
vein (for collection of blood from the systemic circulation) 
and the hepatic portal vein (for collection of blood from the 
portal vein, i.e. after intestinal absorption and metabolism 
and before liver pe-systemic metabolism). After recovery, 
the rats were orally dosed by gavage (same dose, volume 
and formulation as described above), and blood samples 
(50 µL) were collected at 0.25, 0.5, 1, 2, 4, 7, and 24 h con-
comitantly from the 2 blood vessels. Analyses of parent 
compound concentrations were carried out in blood using 
LC-MS/MS. An aliquot of 30 μL was taken and added to 
200  μL MeCN (including Glyburide (c = 50  ng/mL) as 
internal standard) for protein precipitation. Sample analysis 
was performed on a LC–MS/MS system consisting of an 
AB SCIEX API 5500 QTrap mass spectrometer equipped 
with a TurboIonSpray™ interface (Framingham, USA). 
The MS system was connected to a HTS CTC PAL auto-
sampler (Zwingen, Switzerland) and to a Flux Rheos 2200 
pump system (Reinach, Switzerland). The supernatants 
(2 µL) were injected directly onto the LC-MS/MS system 
for analysis. The test articles and its internal standard were 
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separated with a Phenomenex Kinetex C18 (50 × 2 mm ID, 
2.7 µm pore size). A binary gradient with a mobile phase 
consisting of water (A) and acetonitrile (B) was used for 
the LC-separation. Both mobile phases (A) and (B) were 
acidified with 0.1% formic acid. The elution gradient pro-
gram was as follows: [time (min), (% mobile phase B): (0, 
95) (5.8, 85) (5.81, 99) (6.5, 99) (6.51, 95) (8, 95)]. The 
column temperature was maintained at 50 °C using a col-
umn heater. Under these experimental conditions, the 
LLOQ was 0.4 ng/mL.
All animals were maintained under standard housing 
conditions with access to standard pelleted food and water 
ad  libitum throughout experiments. Animal experiments 
were conducted in accordance with Swiss national animal 
welfare regulations, under the ethically approved animal 
experimentation licenses authorized by the Cantonal Vet-




As explained in the introduction, closely related analogues 
to peptide (2) were designed to obtain structurally related 
molecules having high solubility and permeability. The 
decrease in N-methylation was realized by exchanging the 
N-methylated Tyr residue in (2) for alternative residues 
with a standard non-methylated amide bond. To compen-
sate for this increase in polarity by returning to a standard 
amide bond, the phenolic OH of the Tyr was eliminated 
resulting in cyclic peptides bearing varying hydropho-
bic side chains (Fig. 1). As an overall effect, polarity was 
moved from the side chain to the backbone to enable a 
better shielding as compared to corresponding options for 
side chain functionalities. Thus, for the replacement of Tyr, 
we have foreseen residues Phe, Abu, and Ala resulting in 
peptides (3), (4), and (5) to assess the effects of bulk on 
the ability to shield the more polar amide bond, to monitor 
the influence on physico-chemical parameters like solubil-
ity, and finally to investigate pharmacokinetics (PK). The 
corresponding peptides were assembled on the solid phase 
and backbone cyclized in solution similar to procedures as 
reported earlier (Lewis et al. 2015).
In‑silico and In Vitro Profiling
In-silico analyses were initiated in the first instance to 
determine the SAPSA, in particular for each of the 3 
designed analogues. The SAPSA calculation differs from 
the classical PSA (Ertl et  al. 2000), which is widely used 
to estimate the bio-availability of small molecules, in two 
aspects: (a) the area is computed for a solvent probe sphere 
in contact with nitrogen, oxygen, and their bound hydrogen 
atoms, rather than the surface on the atoms themselves; and 
(b) the surface is computed by averaging over an ensemble 
of 3-dimensional structures, instead of a sum of tabulated 
values of O and N atoms depending on their bond topol-
ogy and independent of the 3-dimensional structure, in par-
ticular the actual solvent exposure. As a consequence, the 
SAPSA considers the average solvent-accessibility of polar 
atoms. Thus, this algorithm takes into account the ability of 
polar atoms to form intra-molecular hydrogen bonds or the 
effect of shielding from exposure to solvent by other apolar 
moieties. Comparing the SAPSA values for cyclic hexa-
peptides (3), (4), and (5), calculations indicate the Abu-
peptide (4) with a SAPSA of 66 Å2 to be the most favora-
ble compound, followed by the Phe-analogue (3) with a 
SAPSA of 70 Å2 (Table 1). In our experience, cyclic hexa-
peptides with a SAPSA of <80  Å2 are considered highly 
permeable, whereas above 150  Å2 only a low permeabil-
ity is expected for this scaffold. The in-silico assessment 
illustrates that both aliphatic and aromatic shielding can be 
effective in masking polarity. The finding that the largest 
side chain, Phe in compound (3), which would be expected 
to lead to the best solvent shielding of the backbone, has 
not resulted in the lowest SAPSA highlights the fact that 
structural changes can have both an indirect and a direct 
effect on solvation. In the first case, slightly altered scaffold 
geometries result in a different conformer distribution and 
lead to changes with respect to the overall distribution of 
the polar surface area. In addition or alternatively, shield-
ing by steric hindrance of solvent contacts has an influence 
on the SAPSA. In this study, introduction of a Phe residue 
is increasing the solvent shielding over an Ala in the same 
position, presumably by steric hindrance of solvent access. 
However, the predicted higher solvent accessibility of 
compound (3) in comparison with the Abu analogue (4) is 
expected to be derived from the influence on the conformer 
distribution of the peptide, shifting the equilibrium towards 
higher exposure of the backbone. According to structural 
clustering, the dominant conformations of peptides (3)–(5) 
as illustrated in Fig. 2a–c were obtained. The green colored 
solvent accessible polar surface area visually represents the 
exposed polarity. According to Table 1, the SAPSA could 
be substantially reduced compared to the starting structure 
(2), in particular for peptide (4). As a next step, we investi-
gated further the Ala versus Abu side chain, due to the sig-
nificant difference between these closely related peptides 
(4) and (5). In order to map the contribution of the side 
chain, the trajectory of peptide (4) (20 ns, 20,000 confor-
mations stored) was modified to replace the terminal  CH3 
of the Abu side chain by a hydrogen atom. Effectively, on 
the basis of the scaffold geometry of peptide (4), a modified 
trajectory for peptide (5) was obtained followed by SAPSA 
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Table 1  In vitro and physicochemical data on cyclic hexapeptides
Peptide Sequence SAPSA (Å2) SFC (min) Sol. (mM, 
pH = 6.8)
Log PAMPA (m/s) Class MDCK







146 ± 14 4.8 0.151 <−6.4 L 2.0 95 92
(2) [NMe-Tyr-Leu-NMe-D-Leu-
NMe-Leu-Leu-D-Pro]
127 ± 10 4.1 0.026 <−4.6 H 11.4 63 >99
(3) [Phe-Leu-NMe-D-Leu-NMe-
Leu-Leu-D-Pro]
70 ± 10 2.9 0.030 −4.0 H 11.6 488 >99
(4) [Abu-Leu-NMe-D-Leu-NMe-
Leu-Leu-D-Pro]
66 ± 9 2.7 0.602 −4.3 H 4.0 324 >99
(5) [Ala-Leu-NMe-D-Leu-NMe-
Leu-Leu-D-Pro]
85 ± 13 2.8 >1.000 −4.6 H 2.7 654 >99
Fig. 2  Representation of the solvent-accessible polar surface (green 
dots) for cyclic hexapeptides, a SAPSA of the most populated con-
formational cluster for peptide (3) [Phe-Leu-NMe-D-Leu-NMe-Leu-
Leu-D-Pro], b SAPSA of most populated conformation cluster for 
peptide (4) [Abu-Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro], c SAPSA 
of most populated conformation cluster for peptide (5) [Ala-Leu-
NMe-D-Leu-NMe-Leu-Leu-D-Pro]
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calculation. Figure  3 shows in red the SAPSA values, 
averaged in intervals of 1  ns, for this modified trajectory 
mimicking peptide (5). The corresponding SAPSA values 
are only slightly larger than those of peptide (4) in green. 
Throughout the simulation, values are considerably lower 
than for the original molecular dynamics of peptide (5) rep-
resented in blue. According to these results, the effect of 
the additional methyl-group in peptide (4) (Abu side chain) 
is almost entirely related to an influence on the scaffold’s 
conformation rather than caused by shielding polar atoms 
in the vicinity of the side chain.
Next, we applied SFC-analysis to compare calculations 
related to polar surface area with experimentally derived 
data. The retention time on a SFC-column containing 
H-bond acceptors and donors has been demonstrated to 
reflect the exposure of polar groups in the apolar environ-
ment applied during the chromatography process (super-
critical  CO2) (Goetz et  al. 2014a, b). Thus, calibrated 
SFC retention times can be compared to the SAPSA val-
ues obtained from molecular dynamics. As indicated in 
Table 1, the ranking according to the in-silico assessment 
agrees very well with the measured SFC retention time. As 
a result, shielding of polar atoms under SFC conditions is 
realized most optimally in the Abu derivative (4) leading to 
a short retention time of 2.7 min. Interestingly, the trade-off 
- elimination of the phenol to reduce polarity and to reduce 
the degree of N-methylation–led to excellent solubility val-
ues for the new derivatives (4) and (5) incorporating ali-
phatic side chains (Table  1). In addition, the results from 
the PAMPA assay agree quite well indicating high perme-
ability for peptides (2)–(5). However, in this case the best 
permeability was attributed to the Phe analogue. MDCK 
data are less consistent, but also suggest high permeability 
for peptide (3) and are broadly in agreement with the other 
assessments. However, most likely in the case of peptide 
(5), for which the MDCK assay is not aligned with PAMPA 
Fig. 3  SAPSA during molecular dynamics simulation for peptide (4) 
in green, peptide (5) in blue, and the “truncated” peptide (4) corre-
sponding to peptide (5) but using the trajectory of (4) in red; points 
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and SFC, the low predictability for oral uptake would have 
excluded this candidate from an in vivo experiment. Taking 
into account the in vitro profiling, it seems possible to iden-
tify cyclic peptides with good permeability and solubility.
In order to make predictions of pharmacokinetic prop-
erties of these cyclic peptides, further in  vitro evaluation 
was carried out to determine plasma-protein binding (PPB) 
and metabolic stability in mouse liver microsomes (MLM). 
In terms of PPB, only the low-permeable, non-methylated 
analogue (1) showed a reduced plasma-protein binding of 
92%, which can be attributed to its more polar character-
istics (Table  1). The highly permeable tri-N-methylated 
analogue (2) and the three di-N-methylated analogues (3), 
(4), and (5), all showed very high plasma-protein binding 
>99%, and thus these peptides could not be discriminated 
between each other. In order to predict clearance in  vivo, 
evaluation in  vitro was assessed in MLM. The N-methyl-
ated compound (2) showed medium clearance (CL), while 
the non-methylated peptide, although poorly permeable, 
had a higher microsomal CL (Table 1). The di-N-methyl-
ated compounds (3), (4) and (5) all showed very high CL in 
the MLM assay, and for the Ala-derivative (5) the highest 
in vitro clearance was observed.
I.v. and Per os (p.o.) Study in Mice: Pharmacokinetics 
of the Cyclohexapeptides
The results of the in vivo p.o. study in mice confirmed the 
permeability predicted from the in  vitro data for peptides 
(4) and (5) and for the others only to some degree (Table 2). 
As a result from the in vivo experiments in mice, in Table 2 
three classes for in vivo CL can be identified. The low CL 
group consists of compounds (2) and (3), and one medium 
CL candidate, compound (4) with 49 mL/min/Kg was iden-
tified. The high CL group consists of compounds (1) and 
(5) with 82 and 105 mL/min/Kg, respectively (Table 2). In 
this context it is noteworthy to indicate, that mouse hepatic 
blood flow is around 90  mL/min/kg. In the medium CL 
group, compound (4) achieves the best oral %BAV (bio-
availability on p.o. administration) of 39% suggesting per-
meability can compensate to some extent for clearance. The 
i.v. and p.o. profiles of this Abu-peptide (4) and the Ala-
derivative (5) are provided in Fig. 4a, b. Surprisingly, the 
Phe-peptide (3) shows only a 7% oral %BAV, although it is 
arguably more permeable in terms of PAMPA and MDCK. 
In addition, this peptide exhibits a low CL of only 2 mL/
min/kg. Potentially, its %BAV may have been impacted by 
the low solubility of only 0.03  mM. In this case, in  vitro 
profiling, in particular the MDCK assay, tends to over-pre-
dict the % oral BAV (Table 1). In the high clearance group, 
only compound (5) with a CL of 105 mL/min/Kg achieves 
a medium absolute oral bioavailability of 23%, and has 
an excellent solubility of >1  mM. Interestingly, although 
the AUC p.o. is lower for the Abu-peptide than the Phe-
analogue, the Cmax for peptide (4) is significantly higher 
compared to the Ala- and Phe-analogue (Table 2). In gen-
eral we would conclude, that the MLM assessment does not 
necessarily reflect the in vivo outcome, although the rank-
ing for cyclic peptides (3), (4) and (5) regarding CL are in 
line with in vitro and in vivo data. Overall, the mouse PK 
studies add more data on very much related peptides as pre-
viously studied in mice (Lewis et al. 2015) and rats (White 
et al. 2011), and demonstrate, that good oral bioavailability 
and solubility within one molecule can be achieved.
Hepatic Portal Vein (H.P.V.) Study in Rat: 
Pharmacokinetics of the Cyclohexapeptides
In a follow-up study, we intended to expand our understand-
ing regarding in vivo clearance. In this context, we consid-
ered assessing the role of liver metabolism, and in particu-







































Fig. 4  a Blood concentration i.v. and p.o. from mouse PK study on 
peptide (4). Data are mean ± standard deviation (n = 3 animals), b 
Blood concentration i.v. and p.o. from mouse PK study on peptide (5) 
Data are mean ± standard deviation (n = 3 animals)
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recently (Holenarsipura et  al. 2015). Accordingly, we 
decided to conduct a hepatic portal vein (H.P.V.) study in 
Sprague Dawley rats due to the technical difficulties associ-
ated with a smaller species like mice. Rats were equipped 
with double jugular vein and hepatic portal vein cannula-
tion. A standard jugular vein cannulation experiment was 
run in parallel as a control. The study was designed to 
measure peptide concentrations in the hepatic portal vein 
after absorption by the intestine before any liver metabo-
lism could have commenced and to compare these values 
to the peptide concentration measured in circulation. Since 
we were intrigued with the difference in CL between the 
two closely related compounds (4) and (5), these peptides 
were considered for the H.P.V. study in the first instance, 
as both exhibit good solubility properties. In order to avoid 
ambiguity, which may result from differential stability as a 
result of proteolytic events, for compounds (1)–(5) stabil-
ity studies were carried out in blood, kidney, and liver cell 
homogenate (see Supplementary Figures S3 A-E). All five 
cyclic peptides proved to be stable under these conditions, 
and as indicated above, peptides (4) and (5) were selected 
for the H.P.V. experiment. As illustrated in Fig. 5a, b, there 
is excellent reproducibility for the control jugular vein 
study compared to the H.P.V. study in terms of exposure. 
With respect to the reduction of exposure resulting from the 
liver first pass effect, it is easy to discriminate between the 
two cyclohexapeptides (4) and (5) (Table 3). For the Abu 
derivative (4), only a moderate metabolism is observed 
(11% first pass effect), while the Ala-peptide shows a 77% 
liver first pass effect. The high exposure in the portal vein 
for the Abu-analogue (4), reflected in the AuC (area under 
the curve) value of 1839  nM/h, can be attributed to its 
increased permeability as discussed above. The clearance 
and %BAV determined in this experiment fit quite well with 
the previous mouse study. This clear-cut result with respect 
to the pronounced difference in the first pass liver effect 
came as a surprise, since both cyclic peptides studied dif-
fer only by one methylene group. In addition, a pronounced 
effect regarding liver metabolism has not been reported for 
this type of molecules. The differential behavior of peptides 
(4) and (5) may be explained by subtle effects of the side 
chain on the altered scaffold geometry, and obviously has 
a profound effect on the in vivo pharmacokinetics of these 
two compounds.
Discussion
Cyclic peptides offer a large spectrum of opportuni-
ties for the discovery of novel therapeutics (Whitty et  al. 
2016; Lewis et  al. 2015; White et  al. 2011), particularly 
Fig. 5   a Compound (4) [Abu-Leu-NMe-D-Leu-NMe-Leu- Leu-D-Pro] H.P.V study and control jugular vein study, b Compound (5) [Ala-Leu-
NMe-D-Leu-NMe-Leu-Leu-D-Pro] H.P.V study and control jugular vein study (the 24 h point for control jugular vein was below the LLOQ)
Table 3  Summary of data from a single rat hepatic portal vein exper-
iment (dose i.v. and p.o.: 3 mg/kg)
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considering difficult targets like protein–protein interac-
tions, for which small molecule inhibitors with sufficient 
affinity and specificity are difficult to identify. By extending 
the chemical space of ligands beyond the 500 MW citerion, 
cyclic peptides are able to target binding surfaces that are 
more flat and less productive in terms of binding efficiency 
than, for example, the enzymatic pocket of a kinase or pro-
tease. However, macromolecules also encounter important 
challenges in the optimization of their “drug-like” proper-
ties, e.g. permeability, and in particular oral bioavailability. 
In the chemical space of molecules beyond the “rule-of-
five” (Veber et al. 2002; Lipinski et al. 2001), it has been 
shown that the shielding or “masking” of polarity (Biron 
et al. 2008) can lead to significant improvement in perme-
ability and as a consequence also lead to an enhancement 
of oral uptake.
As mentioned in the introduction, various strategies to 
reduce polar surface area have been investigated. N-meth-
ylation has been applied for quite some time (White et al. 
2011; Nielsen et  al. 2012; Beck et  al. 2012; Rand et  al. 
2012; Alex et al. 2011), but only recent contributions have 
demonstrated for cyclic penta- and hexaleucine peptides, 
that oral absorption can be achieved even in the absence 
of N-Methylation (Hill et  al. 2014). In this special case, 
shielding was achieved by incorporation of bulky amino 
acids. In addition, NMR (Wang et al. 2014) has been shown 
to be a valuable tool to verify intramolecular hydrogen 
bonds, which are of prime importance in shielding polar-
ity and in evaluating the effect of N-methylation on con-
formation. Design, and production of libraries inspired by 
peptidic natural products such as Sanguinamide A (Nielsen 
et  al. 2012), Guangomide A and Phepropeptide (Nielsen 
et al. 2014; Hewitt et al. 2015; Schwochert et al. 2016) have 
also been demonstrated to be a promising strategy for the 
identification of permeable peptides and understanding the 
underlying principles. In particular, recent investigations 
on cyclic peptides derived from Sanguinamide A resulted 
in a molecule exhibiting solvent-dependent flexibility and 
improved permeability (Bockus et  al. 2015). In addition, 
albeit only on the basis of Caco-2 data, peptoid-type modi-
fications, described from the same group, may offer more 
opportunities to add on polar side chains (Furukawa et al. 
2016). Furthermore, new methods such as SFC (Goetz 
et al. 2014a, b) and the computational “solvent accessible 
polar surface area” (Lewis et al. 2015) provide more oppor-
tunities to support the design of permeable macrocycles. In 
addition to permeability, however, proteolytic degradation 
and metabolism are key aspects in determining oral bio-
availability. In contrast to their linear counterparts, mac-
rocyclic peptides (Kwon and Kodadek 2007) have more 
restricted conformational freedom. Firstly, this contributes 
to an increased proteolytic stability. Secondly, cyclization, 
due to the absence of exposed termini reduces the polarity, 
and therefore, the likelihood for intra-molecular hydrogen 
bonding (White et al. 2011) is increased.
Embarking from compounds (1) and (2), which have 
been extensively discussed in our previous publication 
(Lewis et  al. 2015), we established the differential effects 
of hydrophobic shielding. As a result, for the in vitro profil-
ing as well as for the in  vivo experiments, subtle confor-
mational changes play an important role for the properties 
of the side chain variations investigated. Interestingly, the 
SFC retention time and PAMPA values correlate quite well 
with the observed oral bioavailability in mice and rats, 
however, there is a need for additional assays to enable a 
better in vivo predictability. This statement also holds true 
for the assessment of metabolic stability by liver micro-
somal assays, which may expose an unnatural high pro-
teolytic activity, and for this reason, may not really reflect 
the in  vivo situation. Furthermore, the PK studies clearly 
pointed out differences in oral uptake, which was gratifying 
as we could not necessarily anticipate identifying analogues 
with one less N-methyl, good solubility, and an oral bio-
availability >30%. The pronounced difference in clearance 
for the Ala versus the Abu analogue prompted us to con-
duct the H.P.V. experiment. While the differential perme-
ability, reflected by the increased exposure for the Abu pep-
tide, could be rationalized based on the in vitro profiling, 
the drastic first liver pass effect for the Ala peptide came 
as a surprise. We speculate that Cytochrome P450 enzymes 
hold responsible for this phenomenon, and we are looking 
forward to studying the oxidative metabolism of compound 
(5). In principle, lower AUC values following oral admin-
istration in the in vivo experiments, especially for peptide 
(5), could also result from intestinal Cytochrome P450 
activity. As a next step, we foresee the identification of the 
metabolites for these cyclic peptides, in order to learn what 
features are important for processing and how metaboliza-
tion can be modulated.
Conclusions
Previous reports demonstrated how multiple N-methylation 
and matched hydrogen bond pairs across the macrocycle 
(White et al. 2011; Nielsen et al. 2014; Fouche et al. 2016a, 
b) could improve oral bioavailability. In this study, we have 
shown how hydrophobic shielding can contribute to mask-
ing polarity, and thereby enhancing permeability, while 
simultaneously providing excellent solubility. Thus, balanc-
ing permeability with other physico-chemical parameters 
has been successfully demonstrated in this study, while 
increasing passive permeability often occurs at the expense 
of solubility and lipophilicity as indicated in a recent pub-
lication (Thansandote et al. 2015). However, changes in the 
overall scaffold geometry as a result of minute alterations in 
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a particular side-chain have to be considered, especially if 
the design of improved features targets only local improve-
ments. In addition to in vitro validation (Lewis et al. 2015; 
White et al. 2011), the results presented in this contribution 
clearly demonstrate the significant role of liver metabolism, 
and how small structural changes fundamentally influence 
in  vivo effects. In the case of the Abu substitution, both 
enhanced permeability and the more limited metabolism 
in the liver lead to good oral exposure and bioavailability. 
Another aspect relates to the role of transporters regarding 
oral uptake, and in addition, the potential for chiral recog-
nition. A systematic study provided evidence for selective 
carrier-mediated transport based on Caco-2 permeability 
measurements (Marelli et  al. 2015). However, shortcom-
ings of this type of cellular assays have been recognized, 
and it seems there is some potential for intestinal organoids 
to enable establishing an assay for assessing uptake more 
in line with physiological conditions (Zietek et  al. 2015). 
Any assays or combinations thereof enabling the prediction 
of intestinal permeability and metabolic stability would 
be of assistance in encouraging advances in terms of oral 
exposure. Having gained a more comprehensive under-
standing of both permeability and metabolism for cyclic 
peptides, further experiments on other scaffolds are needed 
to assess the contribution of liver metabolism to clearance, 
in particular for peptides designed for oral bioavailability. 
Interestingly, in this case the more permeable peptide (4) 
is also more resistant to liver metabolism and the question 
may arise, whether this situation is an exception or more a 
standard case. Furthermore, it will be important to know, 
whether there are larger permeable peptides, which due 
to their size may not be metabolized anymore. Acquiring 
a more in-depth understanding of the various processes, in 
particular correlating structural features with the amount of 
metabolization, would definitely help in designing modifi-
cations with increased metabolic stability. In summary for 
peptides able to penetrate membrane barriers, we propose 
investigating liver metabolism at an early point in time dur-
ing therapeutic peptide development.
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